v3.24.1.u1
Collaborations (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Collaborative and license agreements      
AbbVie's receivable from Janssen $ 11,949   $ 11,155
AbbVie's payable to Janssen 31,326   30,650
Janssen Biotech Inc. | Collaborative arrangement      
Collaborative and license agreements      
Milestone payments $ 200    
Share of collaboration development costs responsible by Janssen (as a percent) 60.00%    
Share of collaboration development costs responsible by the entity (as a percent) 40.00%    
Global - AbbVie's share of other costs (included in respective line items) $ 42 $ 55  
AbbVie's receivable from Janssen 250   236
AbbVie's payable to Janssen 275   $ 307
Janssen Biotech Inc. | Collaborative arrangement | United States      
Collaborative and license agreements      
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 283 297  
Janssen Biotech Inc. | Collaborative arrangement | International      
Collaborative and license agreements      
International - AbbVie's share of profits (included in net revenues) 228 240  
Genentech, Inc. | Collaborative arrangement      
Collaborative and license agreements      
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 227 202  
AbbVie's share of development costs (included in R&D) 19 28  
Genentech, Inc. | Collaborative arrangement | United States      
Collaborative and license agreements      
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) $ 9 $ 11